Payment overview · 2025
General Payments
$1,905.18
82 reported records · 25 companies
Healthcare provider profile · identity verified
Douglas R Sinclair, D.O.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WEST COLUMBIA, SC · NPI 1356404107
Verified facts
What the public records show
CMS Open Payments records show Douglas R Sinclair, D.O. received $1,905.18 in general payments during 2025 across 82 reported records.
ABBVIE INC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa, Nurtec Odt, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Qulipta by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fycompa by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ampyra by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $434.29 | 22.8% | 23 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $135.55 | 7.1% | 5 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $132.91 | 7.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $129.91 | 6.8% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $108.52 | 5.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $88.35 | 4.6% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $86.35 | 4.5% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.77 | 4.3% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $78.23 | 4.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.02 | 3.9% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $70.45 | 3.7% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $56.35 | 3.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.27 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.92 | 2.6% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $47.11 | 2.5% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $41.30 | 2.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.97 | 2.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.77 | 1.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $29.61 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.00 | 1.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.68 | 1.4% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $25.15 | 1.3% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $20.63 | 1.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.72 | 1.0% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.35 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,905.18 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $311.49 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $240.49 | 13 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $142.62 | 7 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $135.55 | 5 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $103.46 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $99.62 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $88.35 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $86.35 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $83.70 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $82.77 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $78.23 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $70.45 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.29 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.94 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $50.27 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $48.92 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $30.77 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $26.68 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 41 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 810 | 248 |
| Memantine Hcl | Memantine Hcl | 659 | 181 |
| Gabapentin | Gabapentin | 395 | 103 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 314 | 75 |
| Levetiracetam | Levetiracetam | 250 | 61 |
| Pregabalin | Pregabalin | 223 | 44 |
| Divalproex Sodium Er | Divalproex Sodium | 213 | 59 |
| Topiramate | Topiramate | 211 | 53 |
| Rivastigmine | Rivastigmine Tartrate | 179 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 118 | 27 |
| Primidone | Primidone | 108 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 22 |
| Aimovig Autoinjector | Erenumab-Aooe | 102 | 15 |
| Lamotrigine | Lamotrigine | 102 | 23 |
| Trazodone Hcl | Trazodone Hcl | 101 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 82 | 22 |
| Amantadine | Amantadine Hcl | 79 | 29 |
| Rizatriptan | Rizatriptan Benzoate | 77 | 17 |
| Rivastigmine | Rivastigmine | 75 | 19 |
| Oxcarbazepine | Oxcarbazepine | 69 | 16 |
| Sertraline Hcl | Sertraline Hcl | 69 | 21 |
| Lacosamide | Lacosamide | 62 | 15 |
| Kesimpta Pen | Ofatumumab | 55 | suppressed |
| Baclofen | Baclofen | 52 | 19 |
| Emgality Pen | Galcanezumab-Gnlm | 44 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 41 | 15 |
| Entacapone | Entacapone | 39 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 39 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 38 | 13 |
| Clonazepam | Clonazepam | 37 | 14 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 12 |
| Dalfampridine Er | Dalfampridine | 33 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Fingolimod | Fingolimod Hcl | 28 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 27 | suppressed |
| Austedo | Deutetrabenazine | 25 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Diazepam | Diazepam | 22 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | 12 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Teriflunomide | Teriflunomide | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Prednisone | Prednisone | 16 | 12 |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Fycompa | Perampanel | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Keppra Xr | Levetiracetam | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 12 | suppressed |
| Gocovri | Amantadine Hcl | 12 | suppressed |
| Ampyra | Dalfampridine | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,905.18 · 82 records | ABBVIE INC. | BOTOX, BRIUMVI, Exablate, FYCOMPA, Fintepla, Gamunex-C, HYQVIA, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PONVORY, QULIPTA, REXULTI, Rystiggo, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error